Expanded Access to Tipifarnib

NCT04809233 | Unknown

• 1 other identifier: Expanded Access to Tipifarnib
• Study Type: expanded_access
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

Requests for single patient expanded access to tipifarnib may be considered for adult patients with HRAS mutations or peripheral T Cell Lymphoma (PTCL). To request access, use Responsible Party contact information provided in this record. Expanded access for tipifarnib is only available in the United States.

Conditions

HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)

Interventions

Tipifarnib DRUG

Tipifarnib

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)

You may not qualify if:

• Diagnosed with HRAS mutations or peripheral T Cell Lymphoma (PTCL).
• Adult, ages 18+.
• Have exhausted appropriate standard treatments without success and no comparable or satisfactory alternative treatment is available or exists to treat the disease or condition.
• Is ineligible for participation in any ongoing clinical study of the investigational drug, which includes lack of access due to geographic limitations.
• Meets any other pertinent medical criteria for access to the investigational drug, as established by the Kura Oncology

Sponsors & Collaborators

• Kura Oncology, Inc.: lead

MeSH Terms

Conditions

Lymphoma, T-Cell, Peripheral

Interventions

tipifarnib

Condition Hierarchy (Ancestors)

Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Central Study Contacts

Kura Medical Information

CONTACT

844-KURAONC (844-587-2662); medinfo@kuraoncology.com

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 18, 2021
• First Posted: March 22, 2021
• Last Updated: June 29, 2026

Record last verified: 2026-06